Enliven Therapeutics Entered into a Definitive Merger Agreement with Imara for ~$594.1M
Shots:
- Enliven has an equity value of $324.6M, ~$164.5M in PIPE financing from investors. Imara has a net cash value b/w $75M to $95M and will receive additional net cash of $10M upon closing of the merger
- The combined company will have ~$300M in cash to advance Enliven’s pipeline through multiple clinical milestones and provide a cash runway into early 2026 & the transaction is expected to close in Q1’23
- The combined company focuses on advancing Enliven’s pipeline of precision oncology product candidates & will operate under the name Enliven Therapeutics, Inc. & trade on the Nasdaq under the ticker symbol ELVN. Imara stockholders will own ~16% & Enliven stockholders will hold ~84% of the combined company on a pro forma basis
Ref: Globenewswire | Image: Imara
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
